VLX-1005

DRUG3 trials

Sponsors

Veralox Therapeutics

Conditions

Heparin Induced ThrombocytopeniaHeparin-induced ThrombocytopeniaSafety and Tolerability in Healthy VolunteersThrombocytopenia, Immune

Phase 1

Phase I Study of VLX-1005 in Healthy Subjects

CompletedNCT04783545

Veralox TherapeuticsSafety and Tolerability in Healthy Volunteers

Start: 2021-03-24End: 2022-01-11Updated: 2022-04-28

A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

CompletedNCT05325346

Veralox TherapeuticsHeparin-induced Thrombocytopenia

Start: 2022-03-07End: 2022-04-14Updated: 2023-01-11

Phase 2

A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia

TerminatedNCT05785819

Veralox TherapeuticsHeparin Induced Thrombocytopenia, Thrombocytopenia, Immune

Start: 2023-09-26End: 2025-11-17Updated: 2025-11-25